Cardiowise, Inc.

Unprecedented image diagnostic insights in a single heartbeat.

  • Stage Full Product Ready
  • Industry Healthcare Services
  • Location Fayetteville, AR, USA
  • Currency USD
  • Founded January 2012
  • Employees 4
  • Incorporation Type C-corp
  • Website

Company Summary

CardioWise, Inc. has developed an advanced Machine Learning (ML) Platform for cardiac imaging. We provide unprecedented new diagnostic insights to physicians by utilizing commonly available clinical images and delivering quantitative, meaningful results via the existing physician workflow. CardioWise ML analyses increase objectivity in decision-making; and improve day-to-day clinical cardiac practice, saving lives, while reducing the cost of care worldwide.

Heart Disease is the leading cause of death. The key to survival is early detection, effective intervention and post treatment monitoring. Since there is no single diagnostic test that can deliver quantitative results to assess heart contractile function, providers have utilized multiple, qualitative surrogate imaging tests to determine the course of treatment. In the US $17 billion are spent yearly on cardiac diagnostic scans, many of which are unnecessary.

Leveraging patented ML software algorithms, CardioWise provides simple, easy-to-use 4D quantitative images of heart function on any mobile device over a secure cloud portal to cardiologists, referring physicians and patients satisfying the “Meaningful Use” criteria. CardioWise is the first Machine Learning (ML) solution developed to provide caregivers with a 4D cardiac CT data analysis in a quantitative image needed to accurately and easily assess the viability of the patient’s heart.

CardioWise ML analysis produces a highly accurate mathematical model of the heart that measures strain in 4D and compares it to a normal database of healthy hearts. Results are displayed in a color 3D model in which blue is normal and red is not normal. This technique will become the gold standard for the diagnosis of cardiovascular disease.

The advantages of CardioWise analysis are:
Safety—Non-invasive and ultra low radiation
Efficient & EMR Compliant—Provides all physicians access to the same easy to interpret data
Quantitative & Normalized—Quantitatively defines the response of an intervention (drug, device, or surgery)
Unbiased—Allows comparison of information for clinical trials
Cost Effective—Reduces unnecessary scans and reduces cost

CardioWise plans to go to market with a Cloud-based, Software as a Service (SaaS) business model where subscribers can upload CT images over a HIPAA-compliant, secure connection and receive a 3D strain analysis of the patient’s heart in under 10 minutes. The SaaS model represents additional growth pathways through data mining. The company plans to utilize both channel partners as well as a direct sales effort to capitalize on the strengths and advantages of SaaS such as easy, inexpensive access for channel partners; no expensive installations, software updates or training; trial subscriptions to attract new customers; no capital expenditures, only operating budgets; no additional personnel; access to latest technology without purchasing new imaging equipment.


  • Calvin Goforth
    Member of the Board

    Dr. Goforth has extensive experience in start-up company development including intellectual property assessment, building strong development teams, raising private and government funding and bringing products to market. Early in his career, Dr. Goforth held positions at NASA and Rocketdyne, where he worked on space shuttle main engine development.

  • Jack Coats
    Chief Executive Officer

    Jack Coats is an entrepreneur and senior manager with over 30 years of experience in leading and commercializing medical device, medical imaging, and software companies. He has attained unprecedented growth and value creation in global organizations by leveraging core competencies, bringing new IP into the company portfolio, and developing and launching innovative new products. He currently serves on several corporate and advisory boards.

  • Geoffrey Dalbow
    Chief Technology Officer

    Geoffrey Dalbow is a proven executive & healthcare technology innovator with extensive experience in the research and development of imaging solutions for the detection and diagnosis of disease. He was able to introduce breakthrough imaging and therapy technologies that transformed the way healthcare is practiced. Geoffrey has guided startups to IPO such as at R2 where he solidified R2-CAD as market share leader and sold it to Hologic for $220M.


  • Amir Pourmorteza, Ph.D.
    Elliot McVeigh, Ph.D.

Previous Investors

  • n/a

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free